Merck KGaA (OTCMKTS:MKKGY) Announces Quarterly Earnings Results

Merck KGaA (OTCMKTS:MKKGY) released its quarterly earnings results on Thursday. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.26), Zacks reports. Merck KGaA had a return on equity of 8.10% and a net margin of 11.20%.

Merck KGaA Stock Performance

MKKGY traded down $1.11 during trading on Thursday, hitting $32.73. The stock had a trading volume of 67,853 shares, compared to its average volume of 94,331. The company has a current ratio of 1.69, a quick ratio of 1.09 and a debt-to-equity ratio of 0.37. The company has a 50 day simple moving average of $31.71 and a 200-day simple moving average of $30.07. The firm has a market cap of $21.15 billion, a PE ratio of 16.87, a P/E/G ratio of 2.92 and a beta of 0.92. Merck KGaA has a 12 month low of $23.73 and a 12 month high of $34.19.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MKKGY. Zacks Research raised Merck KGaA from a “strong sell” rating to a “hold” rating in a report on Tuesday. UBS Group cut shares of Merck KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. Six research analysts have rated the stock with a Hold rating. According to MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Merck KGaA Company Profile

Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.